Cantor Fitzgerald reinstated coverage of Pliant Therapeutics (PLRX) with a Neutral rating and no price target The company is discontinuing the Pase 2b BEACON-IPF study of bexotegrast in idiopathic pulmonary fibrosis, the analyst tells investors in a research note. The firm says that while Pliant has two additional clinical stage programs and a third Phase 1-ready asset, without clear visibility on program prioritization, it remains on the sidelines.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PLRX:
- Hold Rating on Pliant Therapeutics Amidst BEACON-IPF Study Discontinuation and Uncertainty in Pipeline Prioritization
- Pliant Therapeutics Reports Q4 2024 Results and Updates
- Pliant Therapeutics reports Q4 EPS (82c), consensus (96c)
- Pliant Therapeutics options imply 29.4% move in share price post-earnings
- Pliant Therapeutics downgraded at Stifel after bexotegrast study discontinued
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue